10-Q: Intuitive Surgical Q1 2026 Financial Results

Intuitive Surgical reported strong Q1 2026 growth with revenue rising 23% to $2.77 billion, driven by increased da Vinci and Ion procedure volumes.

Summary

• Total revenue reached $2.77 billion, a 23% increase year-over-year.
• Da Vinci procedure volume grew 16% to approximately 847,000 procedures.
• Ion procedure volume grew 39% to approximately 42,700 procedures.
• Operating income rose 48% to $855 million.
• Net income attributable to Intuitive Surgical was $821.5 million, or $2.28 per diluted share.
• The company completed the acquisition of distribution businesses in Italy, Spain, and Portugal for approximately $533.1 million.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong performance, characterized by double-digit growth in both revenue and procedure volumes, despite macroeconomic headwinds and increased tariff costs.

Positives

• Strong revenue growth of 23% year-over-year.
• Robust procedure growth in both da Vinci (16%) and Ion (39%) platforms.
• Operating income margin expansion, with operating income growing 48%.
• Successful launch and adoption of the da Vinci 5 system, with 232 units placed in Q1 2026.
• Gross profit margin improved to 66.1% from 64.7% in the prior year period.

Negatives

• Cash and cash equivalents decreased to $2.01 billion from $3.37 billion at year-end 2025, primarily due to share repurchases and business acquisitions.
• U.S. bariatric procedure volume declined by approximately 10%.
• Increased tariff expenses of approximately $28 million recognized in cost of revenue.
• Service gross profit margin decreased to 63.0% from 65.6% due to higher costs associated with the da Vinci 5 system.

Risks

• Macroeconomic and geopolitical uncertainties, including inflation, interest rates, and conflicts in Ukraine and the Middle East.
• Supply chain constraints and potential cost pressures for semiconductor materials.
• Ongoing antitrust litigation and product liability lawsuits.
• Regulatory risks, including elongated approval timelines and potential changes to tariffs or trade barriers.
• Competitive pressures in China and potential government-imposed limits on robotic surgery pricing.

Future Outlook

The company expects to continue substantial investments in research and development and anticipates that these expenses will increase in the future. Depreciation and amortization expenses are also expected to increase throughout the remainder of 2026 due to infrastructure scaling and recent acquisitions.

Management Comments

• Management emphasizes the 'Quintuple Aim' as the company's north star, focusing on better patient outcomes, better patient experiences, better care team experiences, lower total cost of care, and expanded access.
• Management notes that while the conflict in the Middle East has not resulted in material disruption to supply or delivery, they continue to monitor supplier operations and transportation factors.

Industry Context

StockSavvy.ai notes that Intuitive Surgical continues to maintain a dominant market position in robotic-assisted surgery, though it faces increasing competition from both established medical device giants and emerging domestic players in international markets like China. The shift toward usage-based leasing models reflects a broader industry trend of lowering capital barriers for hospitals.

Comparison to Industry Standards

• Intuitive's 23% revenue growth significantly outpaces typical growth rates for mature medical device companies.
• The company's gross margin of 66.1% remains at the high end of the medical technology sector, reflecting strong pricing power and high-margin recurring revenue from instruments and services.
• The company's R&D investment of 13% of revenue is consistent with high-innovation medical technology peers like Medtronic and Stryker.

Legal Proceedings

• Ongoing antitrust litigation with Surgical Instrument Service Company, Inc. (SIS), with oral argument scheduled for June 25, 2026.
• Consolidated class action antitrust litigation regarding service and repair of EndoWrist instruments.
• Various product liability lawsuits alleging defects in the da Vinci surgical system.

Related Party Transactions

• The company maintains a majority-owned joint venture with Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Stakeholder Impact

• Shareholders: Impacted by significant share repurchases ($1.13 billion in Q1).
• Customers: Benefiting from expanded da Vinci 5 availability and new force feedback instruments.
• Employees: Continued investment in headcount and share-based compensation.

Next Steps

• Continue rollout of da Vinci 5 system in international markets.
• Seek additional FDA clearances for da Vinci SP surgical system indications.
• Continue integration of newly acquired European distribution businesses.
• Prepare for upcoming legal proceedings, including the June 2026 oral argument for the SIS antitrust appeal.

Key Dates

Recommendation

The company demonstrates strong fundamental growth, a dominant market position, and successful execution of its next-generation product rollout, justifying a buy recommendation for long-term investors.

Keywords

Intuitive Surgical, ISRG, da Vinci, Ion, robotic surgery, minimally invasive, medical devices, 10-Q